Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of EQ001 in Subjects With Newly Diagnosed Acute Graft Versus Host Disease

NCT03763318 is registered in ClinicalTrials.gov with Biocon Limited as lead sponsor.

NCT NCT03763318
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03763318 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of EQ001 in Subjects With Newly Diagnosed Acute Graft Versus Host Disease
Lead sponsor
Biocon Limited
Phase
Phase 1/2
Overall status
Completed
Start date
July 15, 2019
Completion date
November 21, 2022
Enrollment
30 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

acute-graft-versus-host disease, agvhd, gvhd, gvhd, acute